Today's Low
₹ 257.35
Today's High
₹ 257.35
52 Weeks Low
₹ 162.10
52 Weeks High
₹ 265.85
Lower
₹ 244.50
Upper
₹ 270.20
Sun Pharma Advanced Research Co. Ltd. is a bio-pharmaceutical company, which engages in the research and development of pharmaceuticals. Its projects include new chemical entity research and novel drug delivery systems. The company was founded on March 1, 2006 and is headquartered in Mumbai, India.
No of shares Outstanding
EPS-TTM
Face Value
Book Value
Net Asset Value
ROE
ROA
ROCE
Dividend Yield
Total Debt
Sales Growth
PAT Growth
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 455.0 | 71.2 | 59.8 | 67.2 | 257.4 | 175.2 | 158.3 | 66.6 | 62.9 | 110.1 | 139.0 | 18.2 | 12.5 |
Total Non-Current Assets | 375.2 | 208.9 | 166.6 | 205.4 | 141.1 | 137.6 | 118.3 | 98.9 | 83.5 | 76.9 | 69.1 | 67.0 | 65.3 |
Total Assets | 830.1 | 280.1 | 229.7 | 272.6 | 398.5 | 312.8 | 276.6 | 166.7 | 146.7 | 187.5 | 209.0 | 85.7 | 77.8 |
Total Current Liabilities | 179.0 | 171.4 | 233.4 | 235.4 | 95.0 | 116.1 | 108.0 | 124.8 | 37.2 | 38.8 | 94.2 | 145.0 | 64.7 |
Total Non-Current Liabilities | 138.4 | 77.4 | 164.6 | 55.9 | 7.2 | 12.0 | 10.4 | 10.0 | 9.7 | 9.5 | 6.3 | 7.2 | 7.5 |
Shareholder's Funds | 512.8 | 31.2 | -168.3 | -18.6 | 296.2 | 184.7 | 158.2 | 31.8 | 99.8 | 139.3 | 108.4 | -66.6 | 5.6 |
Total Liabilities | 830.1 | 280.1 | 229.7 | 272.6 | 398.5 | 312.8 | 276.6 | 166.7 | 146.7 | 187.5 | 209.0 | 85.7 | 77.8 |
The Industry Debt to Equity Ratio stands at 0.13, vs the Debt to Equity Ratio of 0.00, which results in a Negative aspect.
The Industry Quick Ratio stands at 8.33, vs the Quick Ratio of 0.00, which results in a Negative aspect.
The Industry Current Ratio stands at 8.49, vs the Current Ratio of 0.00, which results in a Negative aspect.
The Industry Price to BV stands at 5.93, vs the Price to BV of 0.00, which results in a Negative aspect.
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Income | 238.8 | 137.3 | 253.0 | 76.8 | 182.9 | 78.3 | 181.0 | 161.3 | 155.7 | 167.0 | 87.3 | 29.0 | 58.4 |
Total Expenditure | 452.8 | 324.0 | 387.9 | 386.8 | 334.2 | 320.9 | 303.7 | 224.5 | 190.8 | 133.5 | 104.0 | 98.9 | 65.0 |
Operating Profit(Excl OI) | -203.2 | -179.9 | -129.6 | -300.3 | -137.8 | -237.7 | -109.0 | -60.3 | -32.1 | 43.5 | -15.2 | -68.8 | -5.4 |
Add: Other Income | 10.9 | 6.8 | 5.4 | 9.8 | 13.5 | 4.9 | 13.7 | 2.9 | 3.0 | 10.0 | 1.6 | 1.2 | 1.2 |
Operating Profit | -203.2 | -179.9 | -129.6 | -300.3 | -137.8 | -237.7 | -109.0 | -60.3 | -32.1 | 43.5 | -15.2 | -68.8 | -5.4 |
Less: Interest | 7.6 | 13.3 | 10.7 | 2.7 | 0.1 | 0.1 | 1.8 | 2.2 | 0.2 | 5.6 | 4.0 | 0.3 | 0.1 |
PBDT | -210.8 | -193.2 | -140.2 | -302.9 | -137.9 | -237.8 | -110.8 | -62.4 | -32.3 | 37.9 | -19.1 | -69.1 | -5.5 |
Less: Depreciation Amortization | 11.8 | 10.2 | 10.9 | 9.5 | 7.6 | 8.2 | 8.2 | 7.6 | 7.2 | 3.6 | 3.4 | 3.2 | 3.0 |
PBT & Exceptional Items | -222.6 | -203.4 | -151.1 | -312.4 | -145.4 | -246.0 | -119.0 | -70.0 | -39.5 | 34.3 | -22.5 | -72.2 | -8.5 |
Less: Exceptional Income Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 49.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Profit Before Tax | -222.6 | -203.4 | -151.1 | -312.4 | -145.4 | -197.0 | -119.0 | -70.0 | -39.5 | 34.3 | -22.5 | -72.2 | -8.5 |
Less: Taxation | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 4.0 | 0.0 | 0.0 | 0.0 |
Profit After Tax | -222.6 | -203.4 | -151.1 | -312.4 | -145.4 | -197.0 | -119.0 | -70.0 | -39.5 | 30.3 | -22.5 | -72.2 | -8.5 |
Earnings Per Share | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
The Industry PE Ratio stands at 51.30, vs the PE Ratio of 0.00, which results in a Negative aspect.
The Industry PAT Growth stands at 43.16, vs the PAT Growth of 0.00, which results in a Negative aspect.
The Industry Dividend Yield stands at 0.10, vs the Dividend Yield of 0.00, which results in a Negative aspect.
The Industry PAT Margin stands at 17.61, vs the PAT Margin of 0.00, which results in a Negative aspect.
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Profit Before Tax | -222.6 | -203.4 | -151.1 | -312.4 | -145.4 | -246.0 | -119.0 | -70.0 | -39.5 | 34.3 | -22.5 | -72.2 | -8.5 |
Tax Paid | 5.4 | 4.5 | -1.6 | -9.9 | -4.5 | -10.1 | -20.7 | -13.9 | -2.6 | -8.1 | -0.6 | -0.8 | 0.0 |
Adjustment | 7.0 | 16.7 | 48.8 | 9.4 | -21.8 | 3.8 | -1.1 | 9.2 | 4.7 | 0.9 | 5.7 | 2.9 | 2.7 |
Changes In Working Capital | -222.6 | -203.4 | -151.1 | -312.4 | -145.4 | -246.0 | -119.0 | -70.0 | -39.5 | 34.3 | -22.5 | -72.2 | -8.5 |
Cash Flow after changes in Working Capital | -74.5 | -212.8 | -150.3 | -200.9 | -167.4 | -221.7 | -107.3 | -30.3 | -38.5 | 45.0 | -94.7 | -68.7 | 2.3 |
Cash Flow from Operating Activities | -69.1 | -208.2 | -151.9 | -210.8 | -171.9 | -182.8 | -128.0 | -44.2 | -41.2 | 36.9 | -95.3 | -69.4 | 2.3 |
Cash Flow from Investing Activities | -548.3 | -29.2 | 1.6 | 155.3 | -102.2 | -104.6 | -6.6 | -13.1 | 53.0 | 43.6 | -99.3 | -2.4 | -7.6 |
Cash Flow from Financing Activities | 616.8 | 229.3 | 159.3 | 55.5 | 274.2 | 224.0 | 194.3 | 50.5 | -1.3 | -80.8 | 194.4 | 72.1 | 4.4 |
Net Cash Inflow / Outflow | -0.6 | -8.1 | 9.0 | 0.0 | 0.1 | -63.4 | 59.6 | -6.7 | 10.6 | -0.3 | -0.3 | 0.2 | -0.9 |
Opening Cash & Cash Equivalents | 1.2 | 9.3 | 0.4 | 0.3 | 0.2 | 63.6 | 4.0 | 10.6 | 0.0 | 0.3 | 0.6 | 0.3 | 1.3 |
Closing Cash & Cash Equivalent | 0.6 | 1.2 | 9.3 | 0.4 | 0.3 | 0.2 | 63.6 | 4.0 | 10.6 | 0.0 | 0.3 | 0.6 | 0.3 |
The Industry PCF RATIO stands at 36.20, vs the PCF RATIO of 0.00, which results in a Negative aspect.
The Industry PFCF Ratio stands at 57.99, vs the PFCF Ratio of 0.00, which results in a Negative aspect.
Particulars | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 | Mar 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Sales | 138.6 | 211.8 | 239.5 | 476.9 | 1,310.9 | 315.4 | 284.6 | 252.4 | 621.5 | 278.7 | 219.9 | 280.6 | 218.1 | 176.4 | 1,854.5 | 227.1 |
Total Income | 202.5 | 296.7 | 341.4 | 584.2 | 1,311.2 | 316.0 | 286.4 | 254.6 | 624.9 | 338.5 | 227.9 | 283.9 | 234.1 | 204.6 | 1,861.1 | 258.3 |
Total Expenditure | 1,164.8 | 1,126.5 | 1,261.3 | 1,372.6 | 1,149.1 | 941.4 | 1,066.6 | 917.8 | 734.2 | 830.4 | 762.6 | 784.9 | 847.7 | 1,000.1 | 1,246.7 | 1,210.7 |
PBIDT (Excl OI) | -1,026.2 | -914.7 | -1,021.8 | -895.7 | 161.8 | -626.0 | -782.0 | -665.4 | -112.7 | -551.7 | -542.7 | -504.3 | -629.6 | -823.7 | 607.8 | -983.6 |
Other Income | 63.9 | 84.9 | 101.9 | 107.3 | 0.3 | 0.6 | 1.8 | 2.2 | 3.4 | 59.8 | 8.0 | 3.3 | 16.0 | 28.2 | 6.6 | 31.2 |
Operating Profit | -962.3 | -829.8 | -919.9 | -788.4 | 162.1 | -625.4 | -780.2 | -663.2 | -109.3 | -491.9 | -534.7 | -501.0 | -613.6 | -795.5 | 614.4 | -952.4 |
Interest | 2.6 | 2.6 | 2.6 | 2.1 | 29.3 | 28.6 | 16.3 | 22.2 | 23.3 | 34.1 | 53.7 | 40.2 | 35.0 | 11.6 | 19.7 | 15.7 |
Exceptional Items | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
PBDT | -964.9 | -832.4 | -922.5 | -790.5 | 132.8 | -654.0 | -796.5 | -685.4 | -132.6 | -526.0 | -588.4 | -541.2 | -648.6 | -807.1 | 594.7 | -968.1 |
Depreciation | 31.6 | 31.8 | 31.0 | 29.4 | 31.3 | 30.0 | 27.0 | 25.1 | 25.8 | 25.4 | 25.3 | 26.0 | 27.6 | 27.8 | 27.8 | 27.3 |
Profit Before Tax | -996.5 | -864.2 | -953.5 | -819.9 | 101.5 | -684.0 | -823.5 | -710.5 | -158.4 | -551.4 | -613.7 | -567.2 | -676.2 | -834.9 | 566.9 | -995.4 |
Tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Provisions and contingencies | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Profit After Tax | -996.5 | -864.2 | -953.5 | -819.9 | 101.5 | -684.0 | -823.5 | -710.5 | -158.4 | -551.4 | -613.7 | -567.2 | -676.2 | -834.9 | 566.9 | -995.4 |
Net Profit | -996.5 | -864.2 | -953.5 | -819.9 | 101.5 | -684.0 | -823.5 | -710.5 | -158.4 | -551.4 | -613.7 | -567.2 | -676.2 | -834.9 | 566.9 | -995.4 |
ADDITIONAL INFOS: | ||||||||||||||||
Equity Capital | 324.5 | 324.5 | 324.5 | 324.5 | 275.3 | 271.9 | 271.9 | 271.9 | 263.5 | 263.5 | 262.1 | 262.1 | 262.1 | 262.1 | 262.1 | 262.1 |
Reserves | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
EPS | -3.1 | -2.7 | -2.9 | -2.6 | 0.4 | -2.5 | -3.0 | -2.7 | -0.6 | -2.1 | -2.3 | -2.2 | -2.6 | -3.2 | 2.2 | -3.8 |
Operating Profit Margin | -694.3 | -391.8 | -384.1 | -165.3 | 12.4 | -198.3 | -274.1 | -262.8 | -17.6 | -176.5 | -243.2 | -178.5 | -281.3 | -451.0 | 33.1 | -419.4 |
Net Profit Margin | -719.0 | -408.0 | -398.1 | -171.9 | 7.7 | -216.9 | -289.4 | -281.5 | -25.5 | -197.8 | -279.1 | -202.1 | -310.0 | -473.3 | 30.6 | -438.3 |
The Industry Mcap Growth stands at 17.95, vs the Mcap Growth of -27.84, which results in a Negative aspect.
The Industry Net Sales Growth stands at 25.27, vs the Net Sales Growth of 0.00, which results in a Negative aspect.
Type | Classic | Woodie | Camarilla |
---|---|---|---|
R4 | 257.35 | 257.35 | 257.35 |
R3 | 257.35 | 257.35 | 257.35 |
R2 | 257.35 | 257.35 | 257.35 |
R1 | 257.35 | 257.35 | 257.35 |
Pivot | 257.35 | 257.35 | 257.35 |
S1 | 257.35 | 257.35 | 257.35 |
S2 | 257.35 | 257.35 | 257.35 |
S3 | 257.35 | 257.35 | 257.35 |
S4 | 257.35 | 257.35 | 257.35 |
(All Values are in INR)
1 Day
1 Week
1 Month
Stoch RSI
0.00
Bullish
RSI
26.20
Bullish
ROC
-34.57
Bearish
UltimateOscillator
16.19
Bearish
Williams Indicator
-100.00
Bullish
CCI Indicator
-218.45
Bullish
MACD
-2,663.34
Bearish
Stochastic Indicator
0.00
Bullish
ATR
24.25
High Volatility
Ex-Date | Ratio | Record Date |
---|
Ex-Date | Ratio | Record Date |
---|
Announcement Date | Dividend Amount | Dividend Percentage of FV | Dividend Type |
---|
Date Of Conduct | Board Meeting Details |
---|---|
05-02-2024 | Quarterly Results |
06-11-2023 | Quarterly Results |
07-08-2023 | Quarterly Results |
22-05-2023 | Audited Results Inter alia, to consider and approve and evaluate various options or proposals for raising funds through any of the permissible modes, subject to the receipt of necessary approvals |
22-05-2023 | Audited Results |
13-02-2023 | Quarterly Results |
07-11-2022 | Quarterly Results |
08-08-2022 | Quarterly Results & Inter alia, to consider and evaluate various options or proposals for raising funds through any of the permissible modes, subject to the receipt of necessary approvals.531433 Sungold Capital Ltd. 09/08/2022 Quarterly Results |
17-05-2022 | Audited Results |
04-02-2022 | Quarterly Results |
01-11-2021 | Quarterly Results |
01-09-2021 | SUN PHARMA ADVANCED RESEARCH COMPANY LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/09/2021 ,inter alia, to consider and approve / evaluate various options or proposals for raising funds through any of the permissible modes, subject to the receipt of necessary approvals. |
26-07-2021 | Quarterly Results |
17-05-2021 | Audited Results |
12-05-2021 | Inter alia, to consider and evaluate proposals for raising of funds in one or more tranches by way of issue of Equity Shares or Securities/ Warrants convertible into Equity shares of the Company, through permissible modes including by way of Preferential Issue, subject to the receipt of necessary approvals. |